Dossier assessment
Idelalisib - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Idelalisib - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Idelalisib - Benefit assessment according to §35a Social Code Book V
Press releases
Idelalisib in second-line treatment for CLL: added benefit again not proven
Approval change due to complications / still no relevant data
Additional information
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.
Project details
- Project no.
- A16-18
- Commission
- Commission awarded on 05.04.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Idelalisib (chronic lymphocytic leukaemia) - Addendum to Commission A16-18
Status: Commission completed
-
Dossier assessment
Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed